Category: Edwards Lifesciences
Transcatheter aortic valve implants take center stage at the annual Transcatheter Cardiovascular Therapeutics conference with the latest data dumps from rivals Medtronic and Edwards Lifesciences.
Symetis has been battling Medtronic and Edwards Lifesciences for years in the European transcatheter aortic valve implantation market, and the company's aiming to squeeze out Boston Scientific, St. Jude Medical and other major players in the U.S.
Switzerland-based medical implant maker Symetis is looking to make some major moves in the global transcatheter aortic valve implantation market, and the company's not afraid to take on some of the medtech industry's biggest players.
Group purchasing organization Novation inks a sole-source deal with Edwards Lifesciences for replacement heart valves.
Here's a look at some of the top regulatory stories for medical device companies this week: Philips wins FDA nod for 3D TAVI planning software; Direct Flow wins CE Marks for TAVI device; FDA OKs return of Covidien's Pipeline embolism device; FDA delays UDI rule for contacts, intraocular lenses; Cardiovascular Systems recalls some Diamondback devices on embolism risk
Philips Healthcare wins 510(k) clearance from the FDA for its 3D planning software for transcatheter aortic valve implants.
Medtronic CEO Omar Ishrak says the medical device company's CoreValve replacement heart valve has captured more than 40% of the U.S. transcatheter aortic valve implant market in just 2 quarters.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany